April 8th 2024
The liquid biopsy combining miRNA and CA19-9 had the best validation rates for detecting pancreatic ductal adenocarcinoma.
February 16th 2024
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Completion of Adjuvant Chemotherapy After Pancreatic Resection Linked With Improved Survival
January 17th 2014Completion of 6 cycles of adjuvant chemotherapy, rather than time of initiation, was an independent prognostic factor after resection of pancreatic adenocarcinoma, according to results taken from the phase III European Study Group for Pancreatic Cancer-3.
The War on Pancreatic Cancer: We Are Not There Yet
January 15th 2014After 2 decades of disappointing phase III trials and years of single-agent gemcitabine therapy, the pancreatic cancer community is relieved to expand the front-line armamentarium in patients with mPAC. Here we evaluate the current landscape and ask some provocative questions about response rate, dosing, and predictive markers.
Treatment of Metastatic Pancreatic Adenocarcinoma: New Options and Promising Strategies
January 15th 2014All improvements in outcomes for patients with metastatic pancreatic adenocarcinoma have occurred with the use of cytotoxic agents, which will probably remain the mainstay of treatment for advanced pancreatic adenocarcinoma.
Treatment of Metastatic Pancreatic Adenocarcinoma: A Review
January 15th 2014Gemcitabine monotherapy has been the standard of care for patients with metastatic pancreatic cancer for several decades. Despite recent advances in various chemotherapeutic regimens and in the development of targeted therapies, metastatic pancreatic cancer remains highly resistant to chemotherapy.
Expanding Options for Pancreatic Cancer...So Where Do We Go From Here?
January 15th 2014In light of two recent positive clinical trials for advanced pancreatic cancer, we are currently facing an interesting situation that those of us who treat this disease have not had to deal with previously: what to do with this expanding array of choices?
Pancreatic Cancer Death Rates Changing Along Racial Lines
December 13th 2013Trends in pancreatic mortality have gone in opposite directions for blacks and whites during the last few decades, a pattern which cannot be explained by known risk factors, according to researchers from the American Cancer Society.
Prolonged Pre-Op Chemo Improved Survival in Pancreatic Cancer
December 13th 2013Researchers at Kaiser Permanente were able to achieve complete histopathologic response in more than 40% of initially unresectable patients with pancreatic adenocarcinoma who underwent prolonged preoperative chemotherapy and were subsequently able to undergo surgical resection.
A Large Cystic Pancreatic Mass in a 45-Year-Old Female
July 15th 2013The patient is an otherwise healthy 45-year-old female who presented to her primary care physician with 6 weeks of increasing left upper quadrant abdominal pain with radiation to the back. She underwent an abdominal ultrasound, which revealed a large cystic abdominal mass.
"Missing the Target" in Urothelial Cancer
March 16th 2013Advanced urothelial cancer remains, along with pancreatic cancer, one of the last solid tumors for which essentially no progress has been made for 25 years. It’s time to think out of the box, and to develop novel and creative ways of overcoming the real, but not insurmountable, logistical challenges to carrying out the needed clinical trials.
Keys to Supportive Care in Pancreatic Cancer: Early Palliative Care, Improved Communication
March 15th 2013Optimal supportive care for patients with pancreatic cancer is essential. Putting these interventions into practice requires that oncologists and oncology teams incorporate innovations at both the individual and the system level.
The Challenge of Palliating Pancreatic Cancer
March 15th 2013FDA approval of palliative chemotherapy is largely based on disease-free and overall survival, quality of life, and symptom reduction; the latter should be routinely measured by the treating oncologist. Physician assessments of symptoms underreport symptom severity compared to patient-reported symptom assessments.
ASCO GI: Oral Chemo S-1 Increases Survival in Pancreatic Cancer, Japanese Study Shows
January 29th 2013An oral fluoropyrimidine, S-1, used as an adjuvant therapy in Japanese patients with resected pancreatic cancer has shown an improved overall survival compared with the standard adjuvant therapy gemcitabine (Gemzar).